Venlafaxine
| Subclass of | chemical compound |
|---|---|
| Get use | Medication |
| Chemical formula | C₁₇H₂₇NO₂ |
| Canonical SMILES | CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O |
| Active ingredient in | Effexor |
| World Health Organisation international non-proprietary name | venlafaxine |
| Physically dey interact plus | Solute carrier family 6 member 2, solute carrier family 6 member 4 |
| Legal status (medicine) | prescription drug, boxed warning |
| Pregnancy category | Australian pregnancy category B2, US pregnancy category C |
| Subject has role | selective serotonin reuptake inhibitor, adrenergic uptake inhibitors, serotonin–norepinephrine reuptake inhibitor |
Venlafaxine, dem sell under de brand name Effexor among odas, be an antidepressant medication of de serotonin–norepinephrine reuptake inhibitor (SNRI) class.[1][2] Dem dey use am to treat major depressive disorder, generalized anxiety disorder, panic disorder, den social anxiety disorder.[2] Na studies show say venlafaxine dey improve post-traumatic stress disorder (PTSD) as a recommended first-line treatment.[3] Dem sanso fi use am for chronic neuropathic pain.[4] Dem dey take am orally (dem swallow by mouth).[2] E sanso be available as de salt venlafaxine besylate (venlafaxine benzenesulfonate monohydrate) insyd an extended-release formulation (Venbysi XR).[5]
Common side effects dey include loss of appetite, constipation, dry mouth, dizziness, sweating, insomnia, drowsiness den sexual problems.[2] Severe side effects dey include an increased risk of suicide, mania, den serotonin syndrome.[2] Antidepressant withdrawal syndrome fi occur if dem stop.[2] Na a meta-analysis of randomized trials insyd depression find an increased rate of serious adverse events, particularly sexual dysfunction den anorexia, den chaw non-serious adverse effects, wey dey include nervousness, asthenia, den tremor.[6] Der be concerns dem use during de later part of pregnancy fi harm de baby.[2] Venlafaxine ein mechanism of action no be entirely clear, buh e dey seem to be related to de potentiation of de activity of sam neurotransmitters insyd de brain.[2]
Na dem approve venlafaxine for medical use insyd de United States insyd 1993.[2] E be available as a generic medication.[2] Insyd 2023, na e be de 51st most commonly prescribed medication insyd de United States, plus more dan 13 million prescriptions.[7][8]
References
[edit | edit source]- ↑ "DailyMed - EFFEXOR XR- venlafaxine hydrochloride capsule, extended release". dailymed.nlm.nih.gov. Retrieved 2025-11-19.
- 1 2 3 4 5 6 7 8 9 10 "Venlafaxine Hydrochloride Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 27 November 2020. Retrieved 24 December 2018.
- ↑ Forman-Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, Viswanathan M, Lohr KN, Baker C, Green J (17 May 2018). Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update (Report). Agency for Healthcare Research and Quality (AHRQ). doi:10.23970/ahrqepccer207. PMID 30204376. Archived from the original on 10 July 2018. Retrieved 29 July 2023.
- ↑ "Antidepressants: Another weapon against chronic pain". Mayo Clinic. Archived from the original on 26 October 2021. Retrieved 25 January 2020.
- ↑ "DailyMed - VENLAFAXINE tablet, extended release". dailymed.nlm.nih.gov. Retrieved 2025-11-19.
- ↑ Kamp CB, Petersen JJ, Faltermeier P, Juul S, Siddiqui F, Moncrieff J, Horowitz MA, Hengartner MP, Kirsch I, Gluud C, Jakobsen JC (October 2024). "The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis". Epidemiology and Psychiatric Sciences. 33 e51. doi:10.1017/S2045796024000520. PMC 11561525. PMID 39440379.
- ↑ "Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
- ↑ "Venlafaxine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 18 August 2025.
External links
[edit | edit source]- Dean L (July 2015). "Venlafaxine Therapy and CYP2D6 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520361.
- Translated from MDWiki
- Commons category link from Wikidata
- Antidepressants
- CYP2D6 inhibitors
- Dimethylamino compounds
- Dopamine reuptake inhibitors
- Drugs wey Pfizer develop
- Methoxyphenethylamines
- 4-Methoxyphenyl compounds
- Serotonin–norepinephrine reuptake inhibitors
- Sigma agonists
- Tertiary alcohols
- Drugs wey Wyeth develop